Inclusion Criteria:

• Subjects must meet all of the following criteria to be enrolled in the study:

  1. Subject must provide written informed consent prior to any study related procedures;
  2. Subject must be ≥ 20 and ≤ 80 years of age;
  3. Subject must have a serum creatinine within the investigational site's normal range.
  4. Subject must have liver function tests < 1.5 times the investigational site's normal range.
  5. Subject must have a hematocrit level within 5% of the investigational site's normal range.

Exclusion Criteria:

• Subjects having any of the following criteria at the time of enrollment will be excluded from study entry:

  1. Any clinically significant acute or unstable physical or psychological disease based on medical history or screening physical examination;
  2. Any clinically significant abnormality in the screening laboratory tests or ECG;
  3. Any exposure to any investigational drugs within four (4) weeks prior to Visit 1;
  4. Any exposure to investigational radiopharmaceuticals within four (4) weeks prior to the date of Visit 1;
  5. Any new prescription medications within four (4) weeks of Visit 1;
  6. Subject has a Positive (+) Serum Pregnancy Test, or the possibility of pregnancy cannot be ruled out prior to dosing or is breast-feeding. There are standard pregnancy procedures for use of radiopharmaceuticals in research at MGH.
  7. Subject has experienced any allergic reaction to similar radiofluorinated compounds or agents.